Design, Synthesis and Evaluation of Naphthalimide Derivatives As Potential Anticancer Agents for Hepatocellular Carcinoma

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Mar 1

PMID 28241441

Citations 6

Authors

Chaochao Ge

Liping Chang

Ying Zhao

Congcong Chang

Xiaojuan Xu

Haoying He

Yuxia Wang

Fujun Dai

Songqiang Xie

Chaojie Wang

Affiliations

Soon will be listed here.

Abstract

Two kinds of naphthalimide derivatives were synthesized and evaluated for in vitro their anti-hepatocellular carcinoma properties. Compound with a fused thiazole fragment to naphthalimide skeleton inhibited cell migration of SMMC-7721 and HepG2, and further in vivo trials with two animal models confirmed that compound moderately inhibited primary H22 tumor growth (52.6%) and potently interrupted lung metastasis (75.7%) without obvious systemic toxicity at the therapeutic dose. Mechanistic research revealed that compound inhibited cancerous liver cell growth mostly by inducing G2/M phase arrest. Western blotting experiments corroborated that could up-regulate the cell cycle related protein expression of cyclin B1, CDK1 and p21, and inhibit cell migration by elevating the E-cadherin and attenuating integrin α6 expression. Our study showed that compound is a valuable lead compound worthy of further investigation.

Citing Articles

Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor.

Zhang H, Han L, Wu H, Xu X, Yu M, Chen G Technol Cancer Res Treat. 2024; 23:15330338231225861.

PMID: 38225189 PMC: 10793192. DOI: 10.1177/15330338231225861.

Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors.

Bestion E, Raymond E, Mezouar S, Halfon P Cells. 2023; 12(13).

PMID: 37443736 PMC: 10341243. DOI: 10.3390/cells12131702.

Polyamine-Drug Conjugates: Do They Boost Drug Activity?.

Basagni F, Marotta G, Rosini M, Minarini A Molecules. 2023; 28(11).

PMID: 37298993 PMC: 10254200. DOI: 10.3390/molecules28114518.

Targeting E-cadherin expression with small molecules for digestive cancer treatment.

Song Y, Ye M, Zhou J, Wang Z, Zhu X Am J Transl Res. 2019; 11(7):3932-3944.

PMID: 31396310 PMC: 6684918.

UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway.

Wang Q, Shi W Oncol Lett. 2019; 17(3):2976-2982.

PMID: 30854075 PMC: 6365959. DOI: 10.3892/ol.2019.9890.

References

Chen Z, Liang X, Zhang H, Xie H, Liu J, Xu Y . A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem. 2010; 53(6):2589-600. DOI: 10.1021/jm100025u. View

Buja L, Eigenbrodt M, Eigenbrodt E . Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch Pathol Lab Med. 1993; 117(12):1208-14. View

Wyllie A, KERR J, Currie A . Cell death: the significance of apoptosis. Int Rev Cytol. 1980; 68:251-306. DOI: 10.1016/s0074-7696(08)62312-8. View

Majno G, Joris I . Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995; 146(1):3-15. PMC: 1870771. View

Liang X, Xu K, Xu Y, Liu J, Qian X . B1-induced caspase-independent apoptosis in MCF-7 cells is mediated by down-regulation of Bcl-2 via p53 binding to P2 promoter TATA box. Toxicol Appl Pharmacol. 2011; 256(1):52-61. DOI: 10.1016/j.taap.2011.07.010. View

Kamal A, Bolla N, Srikanth P, Srivastava A . Naphthalimide derivatives with therapeutic characteristics: a patent review. Expert Opin Ther Pat. 2013; 23(3):299-317. DOI: 10.1517/13543776.2013.746313. View

Brana M, Cacho M, Garcia M, de Pascual-Teresa B, Ramos A, Dominguez M . New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J Med Chem. 2004; 47(6):1391-9. DOI: 10.1021/jm0308850. View

Xie S, Li Q, Zhang Y, Li Z, Zhao J, Wang C . BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma. J Pharm Pharmacol. 2012; 64(10):1483-90. DOI: 10.1111/j.2042-7158.2012.01519.x. View

Lv M, Xu H . Overview of naphthalimide analogs as anticancer agents. Curr Med Chem. 2009; 16(36):4797-813. DOI: 10.2174/092986709789909576. View

10.

Banerjee S, Veale E, Phelan C, Murphy S, Tocci G, Gillespie L . Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents. Chem Soc Rev. 2013; 42(4):1601-18. DOI: 10.1039/c2cs35467e. View

11.

. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014; 383(9928):1561-71. PMC: 4022989. DOI: 10.1016/S0140-6736(13)62159-5. View

12.

Seliga R, Pilatova M, Sarissky M, Viglasky V, Walko M, Mojzis J . Novel naphthalimide polyamine derivatives as potential antitumor agents. Mol Biol Rep. 2013; 40(6):4129-37. DOI: 10.1007/s11033-013-2523-5. View

13.

Hershko A . Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1389):1571-5; discussion 1575-6. PMC: 1692665. DOI: 10.1098/rstb.1999.0500. View

14.

Park J, Shin Y, Riew T, Lee M . The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3β signaling pathways. PLoS One. 2014; 9(9):e109055. PMC: 4182637. DOI: 10.1371/journal.pone.0109055. View

15.

Ingrassia L, Lefranc F, Kiss R, Mijatovic T . Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem. 2009; 16(10):1192-213. DOI: 10.2174/092986709787846659. View

16.

Li M, Li Q, Zhang Y, Tian Z, Ma H, Zhao J . Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro. Anticancer Drugs. 2012; 24(1):32-42. DOI: 10.1097/CAD.0b013e328359affd. View

17.

Friedrichs K, Ruiz P, Franke F, GILLE I, Terpe H, Imhof B . High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res. 1995; 55(4):901-6. View

18.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

19.

Liang X, Xu Y, Xu K, Liu J, Qian X . B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells. Mol Cancer Res. 2010; 8(12):1619-32. DOI: 10.1158/1541-7786.MCR-10-0341. View

20.

Tseng H, Chuah Q, Yang P, Chen C, Chao J, Lin M . Securin enhances the anti-cancer effects of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells. PLoS One. 2012; 7(4):e36006. PMC: 3338557. DOI: 10.1371/journal.pone.0036006. View